 CAMBRIDGE, Mass., May 10, 2021 GLOBE NEWSWIRE -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its first-quarter 2021 financial results. The Company also provided updates on its product candidates pelabresib and CPI-0209. 